Pfizer sold its $3 billion stake in Haleon

Pfizer Sells $700M Stake in Haleon, Trimming Ownership to 7.3%
On Jan 15, Pfizer Inc. ( PFE, Financial) announced to sale of about 700 million ordinary shares of Haleon plc through a secondary offering. The sale is 7.7% of Haleon's issued share capital and will be undertaken following an accelerated book-building process dealing with institutional investors.
Pfizer to sell $3 billion stake in Sensodyne maker Haleon
Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday.
Pfizer Sells 700 Million Haleon Shares for $3.05 Billion
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer Further Pares Haleon Stake With £2.5 Billion Sale
Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyAs E-Bikes Boom in NYC,
Pfizer to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.
Pfizer Sells GBP 2.50 Bln Of Shares In Haleon
Wednesday announced the sale of 700 million shares in Haleon Plc (HLN), a British multinational consumer healthcare
UPDATE: Pfizer cuts stake in Haleon to 7% in GBP2.5 billion share sale
The latest disposal reduced Pfizer's interest in Haleon to 7.3% from 15%. JPMorgan and Morgan Stanley acted as joint global coordinators and joint bookrunners for the sale. GSK sold its remaining 4.2% holding in Haleon in May last year.
Why Pfizer sold its $3 billion stake in Haleon
Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each,
Pfizer to sell 700M ordinary shares of Haleon
Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of
Haleon rises Friday, still underperforms market
Shares of Haleon PLC HLN inched up 0.97% to £3.73 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 1.35% to 8,505.22.
Haleon plc (NYSE:HLN) Shares Acquired by Marcum Wealth LLC
Marcum Wealth LLC raised its holdings in shares of Haleon plc (NYSE:HLN – Free Report) by 19.7% in the fourth quarter, ...
devdiscourse2d
Jury Hits Bayer with $100 Million Verdict Over PCB Controversy
A Washington jury ordered Bayer to pay $100 million to individuals sickened by toxic PCBs at a Seattle school, marking the latest courtroom challenge for the company. Meanwhile, Pfizer is reducing its ...
Haleon Pioneers New Era in Pain Management Education at DUPHAT 2025
Haleon unveils new initiative at DUPHAT 2025, offering sophisticated pain management solutions with research and training for ...
Haleon plc (NYSE:HLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Haleon plc (NYSE:HLN – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the seven research ...
devdiscourse3d
EU's Bid to Reform Medical Device Market amidst Trade Tensions
Health news updates include the EU contemplating curbs on Chinese medical device makers, Pfizer reducing its stake in Haleon, toothpaste lawsuits over fluoride, Eli Lilly’s stock drop, biopharma ...